Citicoline in ophthalmologic practice: neuroprotection in ischemic optic neuropathy, diabetic retinopathy and amblyopia

Authors

  • L.P. Novak Shupyk National University of Public Health, Kyiv, Ukraine, Ukraine
  • O.V. Tumanova Shupyk National University of Public Health, Kyiv, Ukraine, Ukraine

DOI:

https://doi.org/10.22141/2309-8147.9.1.2021.229521

Keywords:

citicoline, neurodegeneration, neuroprotection, is­chemic optic neuropathy, diabetic retinopathy, amblyopia

Abstract

Decrease and loss of vision are extremely important problems, quite common conditions that lead to disability. The most common causes are ischemic optic neuropathy, diabetic retinopathy, and amblyopia. The pathogenesis of these disea­ses is characterized by neurodegeneration, loss of structure and function of neurons. Citicoline may be considered for neuroprotection as the drug of choice in these clinical situations. Citicoline has antioxidant and anti-inflammatory properties, it reduces lipid peroxidation and the formation of free radicals, has anti-apoptotic and membrane-protective effects. The drug has a neuromodulatory effect and also contributes to the pre­servation of sphingomyelin, which ensures signal transmission in nerve cells. In ischemic optic neuropathy, oral citicoline can reduce nerve fiber loss and improve retinal ganglion cell function and visual tract function. In diabetic retinopathy, citicoline prevents synapse loss and improves macular and retinal ganglion cell function. In amblyopia, citicoline stimulates the function of neurotransmitters and neuromodulators, including an increase in the activity of endogenous dopamine and, at the same time, an improvement in the vascular aspects of neurological function. Axobrex is a convenient oral form of citicoline. With oral administration, the bioavailability of citicoline exceeds 90 %, Axobrex is non-toxic and very well-tolerated. The dosage regimen of Axobrex is simple, which contributes to satisfactory patient adherence to treatment. The use of Axobrex in patients with ischemic optic neuropathy, diabetic retinopathy, and amblyopia has an optimal balance of benefits and safety and is advisable for neuroprotection.

References

Country Map & Estimates of Vision Loss. Available from: https://www.iapb.org/learn/vision-atlas/magnitude-and-projections/countries/ukraine/ (last accessed 15.03.2021).

WHO. Blindness and vision impairment. Key facts. 26 February 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment (last accessed 15.03.2021).

Barkana Y., Belkin M. Neuroprotection in Ophthalmology: A Review. In: Stem Cell and Gene-Based Therapy. London: Springer, 2006. https://doi.org/10.1007/1-84628-142-3_17.

Hutmacher F. Why Is There So Much More Research on Vision Than on Any Other Sensory Modality? Front Psychol. 2019. 10. 2246. doi:10.3389/fpsyg.2019.02246.

Parisi V., Barbano L., Di Renzo A., Coppola G., Ziccardi L. Neuroenhancement and neuroprotection by oral solution citicoline in nonarteritic ischemic optic neuropathy as a model of neurodegeneration: A randomized pilot study. PLoS ONE. 2019. 14(7). e0220435. https://doi.org/10.1371/journal.pone.0220435.

Qureshi I., Endres J.R. Citicoline: A Novel Therapeutic Agent with Neuroprotective, Neuromodulatory, and Neuroregenerative Properties. Natural Medicine Journal. 2010. 2(6). 5-27.

Hurtado O., Lizasoain I., Moro M.Á. Neuroprotection and recovery: recent data at the bench on citicoline. Stroke. 2011 Jan. 42 (1 Suppl). S33-5. doi: 10.1161/STROKEAHA.110.597435.

Levin Leonard A. Neuroprotection in Optic Neuropathy. Asia-Pacific Journal of Ophthalmology. 2018. 7(4). 246-250. doi: 10.22608/APO.2018299.

Chang M.Y., Keltner J.L. Risk Factors for Fellow Eye Involvement in Nonarteritic Anterior Ischemic Optic Neuropathy. J. Neuroophthalmol. 2019 Jun. 39(2). 147-152. doi: 10.1097/WNO.0000000000000715.

Parisi V., Manni G., Centofanti M., Angrisani A., Ricci B., Bucci M.G. Oral Treatment With Cytidine-5’-Diphosphocholine (Ci­ticoline) Improves Visual Evoked Cortical Responses in Patients With Optic Nerve Diseases. Invest. Ophthalmol. Vis. Sci. 2007. 48(13). 4817.

Parisi V. et al. Cytidine-5′-diphosphocholine (Citicoline): a pilot study in patients with non-arteritic ischaemic optic neuropathy. European Journal of Neurology. 2008. 15(5). 465-474. https://doi.org/10.1111/j.1468-1331.2008.02099.x.

Utami A.N. et al. The Effect of Citicoline on Electroretino­graphy Abnormalities in Patients with Non-proliferative Diabetic Re­tinopathy. International Journal of Retina. 2019. 2(1). 1-6. DOI: https://doi.org/10.35479/ijretina.2019.vol002.iss001.53.

Matteucci A. Neuroprotective Effects of Citicoline in in Vitro Models of Retinal Neurodegeneration. Int. J. Mol. Sci. 2014. 15(4). 6286-6297. https://doi.org/10.3390/ijms15046286.

Amblyopia Preferred Practice Pattern®. By the American Academy of Ophthalmology. Available from: https://www.aao.org/preferred-practice-pattern/amblyopia-ppp-2017 (last accessed 17.03.2021).

Vagge A., Desideri L.F., Traverso C.E. An update on pharmacological treatment options for amblyopia. International Ophthalmology. 2020. 40(4). 1-7. DOI: 10.1007/s10792-020-01535-w.

Siddiqui A.P., Lennerstrand G., Pansell T., Rydberg A. Citi­coline Treatment of Children with Visual Impairment; a Pilot Study. Pak. J. Ophthalmol. 2012. 28(4). 172-178.

Fresina M., Dickmann A., Salerni A., et al. Effect of oral CDP-choline on visual function in young amblyopic patients. Graefes Arch. Clin. Exp. Ophthalmol. 2008. 246. 143-150. https://doi.org/10.1007/s00417-007-0621-6.

Pawar P.V., Mumbare S.S., Patil M.S., Ramakrishnan S. Effectiveness of the addition of citicoline to patching in the treatment of amblyopia around visual maturity: a randomized controlled trial. Indian J. Ophthalmol. 2014. 62(2). 124-129. doi:10.4103/0301-4738.128586.

Rajguru M., et al. An overview of clinical and therapeuticimplications of citicoline. Narayana Medical Journal. 2014. 3(2). 54-60.

Grieb P. Neuroprotective properties of citicoline: facts, doubts and unresolved issues. CNS Drugs. 2014. 28(3). 185-93. doi: 10.1007/s40263-014-0144-8.

Published

2021-04-29

Issue

Section

Exchange of Experience